
Treatment Guide
Just Diagnosed
Sex & Dating
African American
Stigma
Ask the HIV Doc
PrEP
En Español
News
Voices
Print Issue
Video
Out 100
CONTACT
CAREER OPPORTUNITIES
ADVERTISE WITH US
PRIVACY POLICY
PRIVACY PREFERENCES
TERMS OF USE
LEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use .
One of the hot topics at the 16th Conference on Retroviruses and Opportunistic Infections, held in Montreal in February, was a presentation of data from the North American AIDS Cohort Collaboration on Research and Design that showed an advantage to starting HIV treatment when CD4 counts are still above 500. The NA-ACCORD is a collection of population studies conducted in the United States and Canada between 1996 and 2006 that identified about 9,100 patients who had more than 500 CD4 cells. It then compared people who started anti-HIV treatment when their CD4 counts were still greater than 500 to those who started treatment in the 350 to 500 range. The data showed that the over-500 group had 60% fewer deaths'from either AIDS-related or non-AIDS causes. These results are in agreement with the NA-ACCORD study comparing the effects of starting HIV treatment above (versus below) 350 that was reported in October 2008; it showed a 70% benefit in earlier treatment. Experts are quick to caution that this is an observational study, which means some unknown factors could have caused some patients to start early and others to start later. Although the investigators used sophisticated statistical analyses to control for any bias difference between the two groups, only a prospective double-blind study can provide an unequivocal answer to the question of how early to start treatment. That study, however, could take years to complete, require a very large number of patients, and consume millions of dollars. And since average T-cell count at the time of first HIV diagnosis is already down to 187 in the United States, many question whether that study would be worth it. Meanwhile, evidence continues to mount that uncontrolled HIV adds to the risk of non-AIDS-related illness and death. For example, the multicenter SMART study, which looked at treatment interruptions, showed more heart, liver, and kidney disease in patients who went off treatment compared to those who stayed on. Various treatment guidelines, which call for treatment to start when T-cell counts hit 350, already state that coinfection with hepatitis B or C or the presence of kidney or heart disease are indications to start treatment sooner. And now that current regimens are easier to take and have minimal if any toxicities, we may be about to enter a new era in HIV where everyone is treated as soon as they test positive. Bowers is an HIV specialist and is board-certified in family medicine. He is in private practice in New York City. Learn more about Bowers at https://www.danbowersmd.com
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Plus: Featured Video
Latest Stories
The Pride Store: Discover More LGBTQ+ & Ally Brands Tailor Made for Celebrating Your Identity
November 30 2023 3:04 PM
Shop Your Pride: Dive into LGBTQ+ & Ally Brands with The Grand Opening of The Pride Store
November 28 2023 5:32 PM
These Black Queer Podcasts (Featuring Literally Zero Cis White Gay Men) Deserve Your Ears
November 28 2023 11:55 AM
7 Uplifting Films To Celebrate Trans Awareness Week & Where To Stream Them
November 17 2023 10:25 AM
Out's Deal Guide: Grab Your 50% Off Amazon Fire Tablets & More Recommended Deals on Amazon Today!
November 03 2023 3:44 PM
Unlock Massive Savings at 'The Holiday Shop': Amazon's Hottest Deals of the Season Await!
November 02 2023 2:17 PM
Dianne Feinstein’s Commitment to People Living With HIV Won’t Be Forgotten
November 02 2023 1:27 PM
Trending stories
Most Recent
Recommended Stories for You
Plus Editors
Editor
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.